Reuters logo
BRIEF-Pulmatrix licenses novel drug candidates from Respivert
2017年6月13日 / 下午1点21分 / 5 个月前

BRIEF-Pulmatrix licenses novel drug candidates from Respivert

June 13 (Reuters) - Pulmatrix Inc-

* Pulmatrix licenses novel drug candidates from Respivert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.

* Pulmatrix - through agreement, co gains access to a portfolio of novel drug candidates in a class called kinase inhibitors that co plans to develop Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below